Divis Laboratories
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Divi's Laboratories is positioned for stable revenue growth, supported by management's confident outlook and strategic focus on custom synthesis and complex chemistries. The company is advancing three major capex projects aimed at enhancing production capacity, particularly in the peptide segment, which is expected to drive future revenue. Despite facing challenges such as raw material price volatility and competitive pressures in the generic API market, management anticipates double-digit revenue growth for FY27. Vista's financial outlook reflects this optimism, with improving margins expected as the company capitalizes on favorable pricing dynamics and operational efficiencies. However, potential regulatory changes and geopolitical disruptions could pose risks. Overall, Divi's is well-placed to leverage industry tailwinds, with a target price of approximately ₹10,218 over the next 12 months, indicating an expected upside of 12.29%. Key opportunities include the successful commercialization of new molecules and the expansion of its custom synthesis capabilities, while watchpoints include raw material supply constraints and execution risks associated with ongoing investments
Why We Like This Stock
- Management's focus on expanding capacity in complex chemistries, particularly peptides, is expected to enhance revenue growth
- The company's proactive inventory management and strategic sourcing are mitigating supply chain disruptions and cost volatility
- Improving pricing power in the industry is likely to support margin expansion, aligning with Vista's positive financial outlook
Things To Watch Out For
- Raw material price volatility and geopolitical tensions may impact cost structures and margins in the near term
- Competitive pressures in the generic API segment could limit margin expansion and affect overall profitability
- Regulatory uncertainties surrounding new product approvals may introduce execution risks that could delay revenue realization
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 7,845 | 9,360 | 10,560 | 11,828 | 13,905 |
| Profit Before Tax (Cr.) | 2,167 | 2,915 | 3,462 | 4,232 | 4,812 |
| PBT Margin | 27.6% | 31.1% | 32.8% | 35.8% | 34.6% |
| Net Profit (Cr.) | 1,652 | 2,116 | 2,575 | 3,157 | 3,589 |
| Earnings Per Share | 62.3 | 79.8 | 97.2 | 119.1 | 135.4 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| BofA | ▲ Buy | 8,920 | 03-Aug-2026 |
| Citigroup | ▲ Buy | 11,700 | 03-Aug-2026 |
| Goldman Sachs | ► Accumulate | 9,070 | 03-Aug-2026 |
| ICICI Securities | ▼ Reduce | 6,500 | 03-Aug-2026 |
| JPMorgan | ▲ Overweight | 9,100 | 03-Aug-2026 |
| Jeffries | ▲ Buy | 10,200 | 03-Aug-2026 |
| Kotak Securities | ▼ Sell | 6,925 | 03-Aug-2026 |
| Macguire | ▲ Outperform | 10,200 | 03-Aug-2026 |
| Motilal Oswal | ► Neutral | 7,720 | 03-Aug-2026 |
| Prabhudas Liladhar | ► Accumulate | 8,600 | 03-Aug-2026 |
| Choice Equity | ► Hold | 7,375 | 25-May-2026 |
| Moneycontrol | ► Equalweight | nan | 25-May-2026 |
| Morgan Stanley | ▲ Overweight | 7,904 | 25-May-2026 |
| Elara Capital | ▼ Reduce | 4,486 | 23-Apr-2026 |
Company Overview
Show Company Profile
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.